Vanda Pharmaceuticals Reports Impressive Q3 2025 Financial Growth and Future Plans Vanda Pharmaceuticals showcases a remarkable 31% rise in Fanapt sales for Q3 2025, revealing future ambitions including multiple FDA submissions and pipeline advancements.

Vanda Pharmaceuticals Reports Impressive Q3 2025 Financial Growth and Future Plans #United_States #Washington #Vanda_Pharmaceuticals #Fanapt #BIosanti